Glatter: In practice, many patients labeled non-responders to GLP-1 therapy are experiencing incomplete dosing, early discontinuation because of gastrointestinal side effects, insufficient treatment duration, or competing metabolic drivers such as severe insulin resistance, sleep disruption, sarcopenia, or medication-associated weight gain
The Cardiovascular Biology of Glucagon-Like Peptide-1
Note: The 100mg variant contains a significant amount of peptide
[23] Some experimental studies have suggested that GLP-1 receptors are expressed in the gastrointestinal tract and may have anti-inflammatory properties, though this research is preliminary and has not been translated into clinical practice
Failure to diagnose and treat in time, however, may result in permanent neurological damage, excessive fatigue, depression, memory loss, and other complications
Results vary by peptide and individual, but many patients notice changes within a few weeks